Financhill
Buy
52

INSM Quote, Financials, Valuation and Earnings

Last price:
$77.03
Seasonality move :
34.7%
Day range:
$75.23 - $78.18
52-week range:
$21.92 - $84.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
35.07x
P/B ratio:
49.33x
Volume:
992.9K
Avg. volume:
1.9M
1-year change:
202.37%
Market cap:
$14.1B
Revenue:
$363.7M
EPS (TTM):
-$5.59

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
INSM
Insmed
$102.4M -$1.16 19.4% -27.03% $95.54
ARDX
Ardelyx
$111.2M -$0.00 72.66% -33.34% $10.75
BAX
Baxter International
$2.7B $0.53 -27.96% 589.09% $40.04
BMRN
Biomarin Pharmaceutical
$711M $0.74 14.22% 109.92% $96.72
FOLD
Amicus Therapeutics
$147.9M $0.09 23.74% -81.83% $16.73
OCGN
Ocugen
$300K -$0.05 -100% -- $6.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
INSM
Insmed
$77.77 $95.54 $14.1B -- $0.00 0% 35.07x
ARDX
Ardelyx
$5.42 $10.75 $1.3B -- $0.00 0% 3.82x
BAX
Baxter International
$34.85 $40.04 $17.8B 167.20x $0.17 2.64% 1.39x
BMRN
Biomarin Pharmaceutical
$71.55 $96.72 $13.7B 32.52x $0.00 0% 4.97x
FOLD
Amicus Therapeutics
$9.12 $16.73 $2.8B -- $0.00 0% 5.25x
OCGN
Ocugen
$0.57 $6.75 $167.2M -- $0.00 0% 38.26x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
INSM
Insmed
79.45% 6.110 8.91% 4.99x
ARDX
Ardelyx
46.54% 1.635 12.5% 3.95x
BAX
Baxter International
65.34% 0.281 88.33% 0.54x
BMRN
Biomarin Pharmaceutical
9.52% 0.102 4.75% 2.96x
FOLD
Amicus Therapeutics
66.78% 0.258 13.85% 2.36x
OCGN
Ocugen
49.18% 4.395 12.22% 2.71x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
INSM
Insmed
$78.3M -$245.2M -82.19% -41989.34% -205.36% -$202.8M
ARDX
Ardelyx
$97.9M $8.1M -15.08% -24.57% 9.07% $9.2M
BAX
Baxter International
$959M -$1M -3.07% -8.24% -15.29% $351M
BMRN
Biomarin Pharmaceutical
$611.2M $161.4M 6.92% 8.09% 23% $165.3M
FOLD
Amicus Therapeutics
$134.9M $16M -10.23% -35.23% 13.29% -$4.2M
OCGN
Ocugen
-- -$13.8M -136.46% -171.04% -1811.52% -$10.4M

Insmed vs. Competitors

  • Which has Higher Returns INSM or ARDX?

    Ardelyx has a net margin of -225.53% compared to Insmed's net margin of 4%. Insmed's return on equity of -41989.34% beat Ardelyx's return on equity of -24.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
  • What do Analysts Say About INSM or ARDX?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Ardelyx has an analysts' consensus of $10.75 which suggests that it could grow by 98.34%. Given that Ardelyx has higher upside potential than Insmed, analysts believe Ardelyx is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    ARDX
    Ardelyx
    9 2 0
  • Is INSM or ARDX More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Ardelyx has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.739%.

  • Which is a Better Dividend Stock INSM or ARDX?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or ARDX?

    Insmed quarterly revenues are $104.4M, which are smaller than Ardelyx quarterly revenues of $116.1M. Insmed's net income of -$235.5M is lower than Ardelyx's net income of $4.6M. Notably, Insmed's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 3.82x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    ARDX
    Ardelyx
    3.82x -- $116.1M $4.6M
  • Which has Higher Returns INSM or BAX?

    Baxter International has a net margin of -225.53% compared to Insmed's net margin of -18.6%. Insmed's return on equity of -41989.34% beat Baxter International's return on equity of -8.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    BAX
    Baxter International
    34.84% -$1.00 $20.2B
  • What do Analysts Say About INSM or BAX?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Baxter International has an analysts' consensus of $40.04 which suggests that it could grow by 14.9%. Given that Insmed has higher upside potential than Baxter International, analysts believe Insmed is more attractive than Baxter International.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    BAX
    Baxter International
    3 11 1
  • Is INSM or BAX More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Baxter International has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.696%.

  • Which is a Better Dividend Stock INSM or BAX?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.64% to investors and pays a quarterly dividend of $0.17 per share. Insmed pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or BAX?

    Insmed quarterly revenues are $104.4M, which are smaller than Baxter International quarterly revenues of $2.8B. Insmed's net income of -$235.5M is higher than Baxter International's net income of -$512M. Notably, Insmed's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 1.39x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    BAX
    Baxter International
    1.39x 167.20x $2.8B -$512M
  • Which has Higher Returns INSM or BMRN?

    Biomarin Pharmaceutical has a net margin of -225.53% compared to Insmed's net margin of 16.72%. Insmed's return on equity of -41989.34% beat Biomarin Pharmaceutical's return on equity of 8.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    BMRN
    Biomarin Pharmaceutical
    81.78% $0.64 $6.3B
  • What do Analysts Say About INSM or BMRN?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.72 which suggests that it could grow by 35.18%. Given that Biomarin Pharmaceutical has higher upside potential than Insmed, analysts believe Biomarin Pharmaceutical is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    BMRN
    Biomarin Pharmaceutical
    16 6 0
  • Is INSM or BMRN More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.330, suggesting its less volatile than the S&P 500 by 67.009%.

  • Which is a Better Dividend Stock INSM or BMRN?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or BMRN?

    Insmed quarterly revenues are $104.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Insmed's net income of -$235.5M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Insmed's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 32.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 4.97x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    BMRN
    Biomarin Pharmaceutical
    4.97x 32.52x $747.3M $124.9M
  • Which has Higher Returns INSM or FOLD?

    Amicus Therapeutics has a net margin of -225.53% compared to Insmed's net margin of 9.85%. Insmed's return on equity of -41989.34% beat Amicus Therapeutics's return on equity of -35.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    FOLD
    Amicus Therapeutics
    90.09% $0.05 $584.2M
  • What do Analysts Say About INSM or FOLD?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Amicus Therapeutics has an analysts' consensus of $16.73 which suggests that it could grow by 83.41%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    FOLD
    Amicus Therapeutics
    8 3 0
  • Is INSM or FOLD More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.690, suggesting its less volatile than the S&P 500 by 30.977%.

  • Which is a Better Dividend Stock INSM or FOLD?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or FOLD?

    Insmed quarterly revenues are $104.4M, which are smaller than Amicus Therapeutics quarterly revenues of $149.7M. Insmed's net income of -$235.5M is lower than Amicus Therapeutics's net income of $14.7M. Notably, Insmed's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 5.25x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    FOLD
    Amicus Therapeutics
    5.25x -- $149.7M $14.7M
  • Which has Higher Returns INSM or OCGN?

    Ocugen has a net margin of -225.53% compared to Insmed's net margin of -1816.75%. Insmed's return on equity of -41989.34% beat Ocugen's return on equity of -171.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    OCGN
    Ocugen
    -- -$0.05 $58.3M
  • What do Analysts Say About INSM or OCGN?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1078.83%. Given that Ocugen has higher upside potential than Insmed, analysts believe Ocugen is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    OCGN
    Ocugen
    2 0 0
  • Is INSM or OCGN More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.

  • Which is a Better Dividend Stock INSM or OCGN?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or OCGN?

    Insmed quarterly revenues are $104.4M, which are larger than Ocugen quarterly revenues of $764K. Insmed's net income of -$235.5M is lower than Ocugen's net income of -$13.9M. Notably, Insmed's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 38.26x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    OCGN
    Ocugen
    38.26x -- $764K -$13.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock